ES2077863T3 - Deteccion de necrosis celular por medio de analisis de deteccion de la espectrina y de los productos de descomposicion de esta ultima. - Google Patents

Deteccion de necrosis celular por medio de analisis de deteccion de la espectrina y de los productos de descomposicion de esta ultima.

Info

Publication number
ES2077863T3
ES2077863T3 ES91913322T ES91913322T ES2077863T3 ES 2077863 T3 ES2077863 T3 ES 2077863T3 ES 91913322 T ES91913322 T ES 91913322T ES 91913322 T ES91913322 T ES 91913322T ES 2077863 T3 ES2077863 T3 ES 2077863T3
Authority
ES
Spain
Prior art keywords
detection
bdp
spectrin
sample
spectrine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91913322T
Other languages
English (en)
Inventor
Gary S Lynch
David D Eveleth Jr
Peter A Seubert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of ES2077863T3 publication Critical patent/ES2077863T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G01N33/561—Immunoelectrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Electrochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

LA INVENCION PROPORCIONA UN METODO PARA LA DETECCION DE PATOLOGIA CELULAR POR MEDIO DE UN INMUNOENSAYO PARA DETERMINAR LA PRESENCIA DE PRODUCTOS ESTABLES DE DESCOMPOSICION, DENOMINADOS BDRS O BDP1 Y BDP2, DE LA ESPECTRINA DE COMPONENTES CITOESQUELETALES. EN UN ASPECTO DE LA INVENCION, LOS COMPONENTES DE UNA MUESTRA DE CELULAS QUE CONTIENEN ESPECTRINA SE SEPARAN FISICAMENTE, POR EXPOSICION A UN CAMPO ELECTRICO POR EJEMPLO, DE TAL FORMA QUE SE SEPARAN EL BDP Y LA ESPECTRINA. A CONTINUACION SE PONEN EN CONTACTO ANTICUERPOS QUE REACCIONEN CON EL BDP CON LA MUESTRA SEPARADA Y SU UNION A ESA PARTE DE LA MUESTRA QUE CONTIENE CUALQUIER BDP DETERMINADO. EN OTRO ASPECTO DE LA INVENCION, SE REALIZA UN ENSAYO, COMO EL ENSAYO ELISA, PARA DETECTAR LA INMUNORREACTIVIDAD TOTAL DE LA ESPECTRINA COMO INDICACION DE LA MUERTE O LA DEGRADACION CELULAR.
ES91913322T 1990-07-26 1991-07-11 Deteccion de necrosis celular por medio de analisis de deteccion de la espectrina y de los productos de descomposicion de esta ultima. Expired - Lifetime ES2077863T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/558,700 US5118606A (en) 1988-09-02 1990-07-26 Methods for detecting cellular pathology by assaying spectrin and spectrin breakdown products

Publications (1)

Publication Number Publication Date
ES2077863T3 true ES2077863T3 (es) 1995-12-01

Family

ID=24230602

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91913322T Expired - Lifetime ES2077863T3 (es) 1990-07-26 1991-07-11 Deteccion de necrosis celular por medio de analisis de deteccion de la espectrina y de los productos de descomposicion de esta ultima.

Country Status (10)

Country Link
US (1) US5118606A (es)
EP (1) EP0540591B1 (es)
JP (2) JP2824150B2 (es)
AT (1) ATE128233T1 (es)
CA (1) CA2088050A1 (es)
DE (1) DE69113273T2 (es)
DK (1) DK0540591T3 (es)
ES (1) ES2077863T3 (es)
GR (1) GR3017459T3 (es)
WO (1) WO1992001935A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444042A (en) * 1990-12-28 1995-08-22 Cortex Pharmaceuticals Method of treatment of neurodegeneration with calpain inhibitors
US5536639A (en) * 1994-03-25 1996-07-16 Cephalon, Inc. Methods for detecting calpain activation by detection of calpain activated spectrin breakdown products
CA2188816C (en) 1996-04-23 2009-09-22 Takeda Chemical Industries, Ltd. Composition containing .alpha.-fodrin or .alpha.- fodrin fragment protein
US6011991A (en) * 1998-12-07 2000-01-04 Technology Patents, Llc Communication system and method including brain wave analysis and/or use of brain activity
US7291710B2 (en) * 2002-09-11 2007-11-06 University Of Florida Research Foundation, Inc. Detection of spectrin and spectrin proteolytic cleavage products in assessing nerve cell damage
AU2005238446B2 (en) * 2004-04-15 2009-07-30 Banyan Biomarkers Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
EP1747282B1 (en) * 2004-04-15 2011-06-08 University of Florida Research Foundation, Inc. Map-2 proteolytic breakdown products as diagnostic biomarkers for neural injury
US8492107B2 (en) * 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
WO2008097618A1 (en) * 2007-02-06 2008-08-14 University Of Florida Research Foundation, Inc. Synaptotagmin and collapsin response mediator protein as biomarkers for traumatic brain injury
US8426565B2 (en) 2007-08-30 2013-04-23 Walter And Eliza Hall Institute Of Medical Research Dendritic cell marker and uses thereof
NO2324360T3 (es) 2008-08-11 2018-06-30
AU2010228108A1 (en) * 2009-03-23 2011-11-03 The Walter And Eliza Hall Institute Of Medical Research Compounds and methods for modulating an immune response
CA2774411A1 (en) * 2009-09-18 2011-03-24 Geert W. Schmid-Schonbein Methods for detecting autodigestion
US9295715B2 (en) 2010-10-02 2016-03-29 The Regents Of The University Of California Minimizing intestinal dysfunction
WO2012170669A1 (en) * 2011-06-07 2012-12-13 Yale University Avenue Biomarkers for assessment of the molecular quality in biospecimens
US11723579B2 (en) 2017-09-19 2023-08-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
EP3731749A4 (en) 2017-12-31 2022-07-27 Neuroenhancement Lab, LLC NEURO-ACTIVATION SYSTEM AND METHOD FOR ENHANCING EMOTIONAL RESPONSE
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
EP3849410A4 (en) 2018-09-14 2022-11-02 Neuroenhancement Lab, LLC SLEEP ENHANCEMENT SYSTEM AND METHOD
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
WO2021108380A1 (en) * 2019-11-26 2021-06-03 Ohio State Innovation Foundation Methods and compositions for cardiovascular disease detection and management

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0432218B1 (en) * 1988-09-02 1995-06-28 The Regents Of The University Of California Method for detecting cellular pathology

Also Published As

Publication number Publication date
EP0540591B1 (en) 1995-09-20
DE69113273D1 (de) 1995-10-26
JPH05508919A (ja) 1993-12-09
JP2824150B2 (ja) 1998-11-11
DE69113273T2 (de) 1996-05-15
CA2088050A1 (en) 1992-01-27
JPH1130615A (ja) 1999-02-02
GR3017459T3 (en) 1995-12-31
ATE128233T1 (de) 1995-10-15
WO1992001935A1 (en) 1992-02-06
DK0540591T3 (da) 1996-02-05
US5118606A (en) 1992-06-02
EP0540591A1 (en) 1993-05-12

Similar Documents

Publication Publication Date Title
ES2077863T3 (es) Deteccion de necrosis celular por medio de analisis de deteccion de la espectrina y de los productos de descomposicion de esta ultima.
ES2157220T3 (es) Aparato de ensayo analitico con control negativo y positivo incorporado.
ES525861A0 (es) Procedimiento de inmunoanalisis para determinar digoxina en una muestra de analisis.
BR9711869B1 (pt) mÉtodo e kit para coletar amostras de espÉcimes lÍquidas para teste analÍtico.
IL120082A0 (en) Method for determining the amount of an amylin receptor binding compound in a sample
DK0660936T3 (da) Op-konverterende reportermolekyle til biologiske og andre assays under anvendelse af laserexcitationsteknik
NL184440B (nl) Proefstrook voor het analyseren van opgeloste stoffen.
BR7607029A (pt) Dispositivo para coleta de especimes liquidos assepticos e dispositivo e processo para recolher um especime asseptico de uma descarga de urina
DK161112C (da) Baeremateriale til anvendelse ved immunbestemmelse,fremgangsmaade til fremstilling af baerematerialet og anvendelse deraf ved immunbestemmelser
ES2077726T3 (es) Kit de ensayo para la determinacion de un analito en una muestra pastosa, en especial en las heces.
DK0496832T3 (da) Inhibering af PADGEM-formidlet cellebinding
ES2192611T3 (es) Procedimiento de eliminacion de la interferencia del factor reumatoide en los dosificados de diagnostico.
ES501734A0 (es) Un procedimiento para la deteccion de anticuerpos en una muestra de ensayo
ES2098406T3 (es) Ensayo funcional y reactivo para la determinacion de fibrinogeno.
ES2122231T3 (es) Inmunoanalisis para la deteccion de colageno tipo i o fragmentos de colageno correspondientes.
DK492185A (da) Screeningtest for omvendt-transkriptaseholdig virus
ES521810A0 (es) Un metodo para identificar y numerar celulas microbianas en una muestra de material desconocido.
ES292495Y (es) Cubeta para analisis fotometrico.
EA200100607A1 (ru) 3,4,5-тризамещенные арилнитроны и содержащие их фармацевтические композиции
ES542864A0 (es) Aparato para la criofijacion de especimenes.
ES279935Y (es) Dispositivo para colocar especimenes biologicos.
DK33991D0 (da) Fremgangsmaade til paavisning af cellepatologi
Abuknesha et al. Evaluation of a polyclonal antiserum to pentachlorothiophenol-acetic acid-KLH immunogen: binding properties and use with heterologous PCP derivatives in ELISA for pentachlorophenol
EP0204579A3 (en) Immunoassay incubation device
SHINOGI et al. Measurement of metallothionein in rat tissues by a chromatographic method using the fluorometry of thiol groups

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 540591

Country of ref document: ES